Legend Biotech (LEGN) Financials

$30.07 +0.96 (+3.30%)

As of 05/20/2025 04:00 PM Eastern

Annual Income Statements for Legend Biotech

This table shows Legend Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Income / (Loss) Attributable to Common Shareholders	-177	-518	-446	-404	-266	-102	-2.78
Consolidated Net Income / (Loss)	-177	-518	-446	-404	-266	-102	-2.78
Net Income / (Loss) Continuing Operations	-177	-518	-446	-404	-266	-102	-2.78
Total Pre-Tax Income	-158	-520	-446	-407	-308	-127	-1.62
Total Operating Income	-331	-471	-479	-403	-234	-135	-1.53
Total Gross Profit	371	47	31	60	70	60	63
Total Revenue	627	285	117	69	75	60	63
Operating Revenue	627	285	117	69	75	60	63
Total Cost of Revenue	256	238	86	9.13	4.56	0.22	0.00
Operating Cost of Revenue	256	238	86	9.13	4.56	0.22	0.00
Total Operating Expenses	702	517	510	463	305	194	65
Selling, General & Admin Expense	284	107	174	150	73	32	3.93
Research & Development Expense	414	382	336	313	232	162	61
Impairment Charge	4.42	0.00	0.00	-	-	-	-
Total Other Income / (Expense), net	173	-49	33	-7.10	-74	7.24	-0.08
Other Income / (Expense), net	173	-49	33	-7.10	6.12	7.24	-0.08
Income Tax Expense	19	-1.86	0.63	-3.61	-42	-26	1.17
Weighted Average Basic Shares Outstanding	367.30M	363.82M	330.13M	308.46M	266.01M	-	-
Diluted Earnings per Share	($0.48)	-	($1.40)	($1.43)	($1.13)	($0.51)	($0.01)
Weighted Average Diluted Shares Outstanding	367.30M	363.82M	330.13M	308.46M	266.01M	-	-
Weighted Average Basic & Diluted Shares Outstanding	367.30M	363.82M	330.13M	308.46M	266.01M	-	-

No quarterly income statements for Legend Biotech are available.

This table details how cash moves in and out of Legend Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Change in Cash & Equivalents	-989	5,408	821	233	372	-127	208
Net Cash From Operating Activities	-935	4,787	433	8.38	-223	-83	308
Net Cash From Continuing Operating Activities	-935	4,787	433	8.38	-280	-79	217
Net Income / (Loss) Continuing Operations	0.00	0.00	0.00	0.00	-308	-127	-1.62
Depreciation Expense	21	11	10	13	9.74	5.20	1.67
Amortization Expense	1.93	1.92	2.48	1.38	0.19	0.06	0.02
Non-Cash Adjustments To Reconcile Net Income	-1,107	4,775	420	-142	35	3.61	197
Changes in Operating Assets and Liabilities, net	149	-0.18	-0.16	137	-16	40	20
Net Cash From Investing Activities	-14	8.81	1.25	-42	-24	-59	-102
Net Cash From Continuing Investing Activities	-14	8.81	1.25	-42	-30	23	-96
Purchase of Property, Plant & Equipment	-14	-	-	-42	-26	-27	-21
Net Cash From Financing Activities	0.00	584	378	323	619	15	2.50
Net Cash From Continuing Financing Activities	0.00	584	378	323	609	15	2.50
Issuance of Debt	0.00	349	378	0.00	-	42	36
Issuance of Common Equity	0.00	234	0.00	323	450	0.00	0.00
Cash Interest Received	37	47	5.58	0.65	-	-	-
Cash Income Taxes Paid	1.55	-	-	0.00	-	-	-

No quarterly cash flow statements for Legend Biotech are available.

This table presents Legend Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	1/1/2020
Total Assets	1,670	1,849	1,331	1,119	722	293
Total Current Assets	1,284	1,498	1,099	950	532	115
Cash & Equivalents	287	1,278	786	689	456	83
Short-Term Investments	0.00	0.66	186	0.00	-	-
Accounts Receivable	6.29	100	0.09	50	75	30
Inventories, net	24	19	10	1.75	1.80	1.16
Prepaid Expenses	131	69	62	14	-	-
Plant, Property, & Equipment, net	99	109	105	103	72	45
Plant, Property & Equipment, gross	99	109	105	103	-	-
Total Noncurrent Assets	110	86	60	48	117	133
Intangible Assets	2.16	4.06	3.41	4.68	2.85	0.52
Other Noncurrent Operating Assets	108	82	57	43	114	132
Total Liabilities & Shareholders' Equity	1,670	1,849	1,331	1,119	1,320	444
Total Liabilities	630	597	587	354	124	141
Total Current Liabilities	278	216	298	229	116	94
Accounts Payable	39	31	33	7.04	5.24	9.59
Other Taxes Payable	21	7.20	9.77	-	-	-
Other Current Liabilities	52	56	71	89	102	72
Total Noncurrent Liabilities	352	381	289	124	8.76	47
Long-Term Debt	301	281	261	120	-	-
Capital Lease Obligations	45	44	20	1.59	-	-
Other Noncurrent Operating Liabilities	0.00	48	0.23	0.40	4.51	5.06
Total Equity & Noncontrolling Interests	1,041	1,251	744	766	1,196	303
Total Preferred & Common Equity	1,041	1,251	744	766	1,196	303
Total Common Equity	1,041	1,251	744	766	1,196	303
Common Stock	0.04	0.04	0.03	0.03	0.03	0.02
Other Equity Adjustments	1,041	1,251	744	766	1,196	303

No quarterly balance sheets for Legend Biotech are available.

This table displays calculated financial ratios and metrics derived from Legend Biotech's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	119.97%	143.70%	70.00%	-8.23%	25.04%	-4.85%	0.00%
EBITDA Growth	73.44%	-17.18%	-9.27%	-81.50%	-78.91%	-182,274.63%	0.00%
EBIT Growth	69.60%	-16.69%	-8.65%	-79.70%	-79.31%	-7,778.65%	0.00%
NOPAT Growth	29.63%	1.67%	-18.73%	-71.98%	-74.22%	-8,671.51%	0.00%
Net Income Growth	65.84%	-16.11%	-10.60%	-51.51%	-162.20%	-3,549.07%	0.00%
EPS Growth	0.00%	0.00%	2.10%	-26.55%	-121.57%	-5,000.00%	0.00%
Operating Cash Flow Growth	-119.53%	1,005.72%	5,066.28%	103.76%	-168.47%	-127.00%	0.00%
Free Cash Flow Firm Growth	44.15%	-28.27%	-38.97%	-5.25%	-46.91%	0.00%	0.00%
Invested Capital Growth	7.36%	94.75%	12.07%	-22.16%	109.07%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	59.15%	16.40%	26.51%	86.73%	93.93%	99.63%	100.00%
EBITDA Margin	-21.49%	-177.98%	-370.13%	-575.86%	-291.16%	-203.50%	0.11%
Operating Margin	-52.81%	-165.08%	-409.10%	-585.76%	-312.56%	-224.33%	-2.43%
EBIT Margin	-25.21%	-182.41%	-380.94%	-596.08%	-304.40%	-212.27%	-2.56%
Profit (Net Income) Margin	-28.22%	-181.75%	-381.48%	-586.38%	-355.16%	-169.37%	-4.42%
Tax Burden Percent	111.95%	99.64%	100.14%	99.11%	86.40%	79.79%	172.28%
Interest Burden Percent	100.00%	100.00%	100.00%	99.25%	135.03%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-92.65%	-180.39%	-285.74%	-223.38%	-156.25%	-277.19%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-98.77%	-157.23%	-268.29%	-209.17%	-140.37%	-270.88%	0.00%
Return on Net Nonoperating Assets (RNNOA)	77.20%	128.45%	226.63%	182.23%	120.69%	210.06%	0.00%
Return on Equity (ROE)	-15.45%	-51.94%	-59.11%	-41.15%	-35.56%	-67.13%	0.00%
Cash Return on Invested Capital (CROIC)	-99.74%	-244.68%	-297.12%	-198.45%	-226.83%	-477.19%	0.00%
Operating Return on Assets (OROA)	-8.99%	-32.72%	-36.38%	-44.56%	-45.00%	-43.51%	0.00%
Return on Assets (ROA)	-10.06%	-32.60%	-36.43%	-43.83%	-52.50%	-34.72%	0.00%
Return on Common Equity (ROCE)	-15.45%	-51.94%	-59.11%	-41.15%	-35.56%	-67.13%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-17.01%	-41.41%	-59.97%	-52.69%	-22.28%	-33.57%	0.00%
Net Operating Profit after Tax (NOPAT)	-232	-329	-335	-282	-164	-94	-1.07
NOPAT Margin	-36.96%	-115.55%	-286.37%	-410.03%	-218.79%	-157.03%	-1.70%
Net Nonoperating Expense Percent (NNEP)	6.12%	-23.16%	-17.45%	-14.21%	-15.88%	-6.31%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-16.72%	-20.90%	-32.68%	-	-	-	-
Cost of Revenue to Revenue	40.85%	83.60%	73.49%	13.27%	6.07%	0.37%	0.00%
SG&A Expenses to Revenue	45.32%	37.44%	148.75%	217.22%	96.94%	53.97%	6.23%
R&D to Revenue	65.93%	134.04%	286.87%	455.27%	309.55%	270.00%	96.20%
Operating Expenses to Revenue	111.96%	181.48%	435.62%	672.49%	406.49%	323.96%	102.43%
Earnings before Interest and Taxes (EBIT)	-158	-520	-446	-410	-228	-127	-1.62
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-135	-507	-433	-396	-218	-122	0.07
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.69	7.94	10.34	8.09	0.43	1.40	0.00
Price to Tangible Book Value (P/TBV)	5.70	7.96	10.39	8.14	0.44	1.40	0.00
Price to Revenue (P/Rev)	9.44	34.83	65.80	90.07	6.92	7.07	6.72
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	23.07	37.20	56.55	50.93	0.44	5.01	0.00
Enterprise Value to Revenue (EV/Rev)	9.53	31.49	59.90	81.84	0.84	5.68	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	1.88	16.19	672.13	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.33	0.26	0.38	0.16	0.00	0.00	0.00
Long-Term Debt to Equity	0.33	0.26	0.38	0.16	0.00	0.00	0.00
Financial Leverage	-0.78	-0.82	-0.84	-0.87	-0.86	-0.78	0.00
Leverage Ratio	1.54	1.59	1.62	0.94	0.68	0.97	0.00
Compound Leverage Factor	1.54	1.59	1.62	0.93	0.91	0.97	0.00
Debt to Total Capital	24.94%	20.64%	27.40%	13.74%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	24.94%	20.64%	27.40%	13.74%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	75.06%	79.36%	72.60%	86.26%	100.00%	100.00%	0.00%
Debt to EBITDA	-2.57	-0.64	-0.65	-0.31	0.00	0.00	0.00
Net Debt to EBITDA	-0.44	1.88	1.59	1.43	0.00	0.00	0.00
Long-Term Debt to EBITDA	-2.57	-0.64	-0.65	-0.31	0.00	0.00	0.00
Debt to NOPAT	-1.49	-0.99	-0.84	-0.43	0.00	0.00	0.00
Net Debt to NOPAT	-0.25	2.89	2.06	2.01	0.00	0.00	0.00
Long-Term Debt to NOPAT	-1.49	-0.99	-0.84	-0.43	0.00	0.00	0.00
Altman Z-Score	6.43	10.04	7.58	10.15	2.26	0.65	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	4.62	6.92	3.69	4.14	4.61	1.22	0.00
Quick Ratio	1.06	6.37	3.26	3.23	4.59	1.20	0.00
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-250	-447	-348	-251	-238	-162	0.00
Operating Cash Flow to CapEx	-6,627.25%	0.00%	0.00%	19.86%	-849.45%	-305.02%	1,469.49%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.36	0.18	0.10	0.07	0.15	0.21	0.00
Accounts Receivable Turnover	11.80	5.70	4.63	1.10	1.43	2.00	0.00
Inventory Turnover	11.83	16.01	14.21	5.15	3.08	0.19	0.00
Fixed Asset Turnover	6.03	2.67	1.13	0.79	1.28	1.33	0.00
Accounts Payable Turnover	7.40	7.50	4.31	1.49	0.61	0.02	0.00
Days Sales Outstanding (DSO)	30.94	64.09	78.77	332.54	255.50	182.56	0.00
Days Inventory Outstanding (DIO)	30.87	22.81	25.69	70.93	118.47	1,910.88	0.00
Days Payable Outstanding (DPO)	49.32	48.65	84.77	245.43	593.94	15,832.08	0.00
Cash Conversion Cycle (CCC)	12.48	38.24	19.69	158.03	-219.96	-13,738.64	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	259	241	124	111	142	68	0.00
Invested Capital Turnover	2.51	1.56	1.00	0.54	0.71	1.77	0.00
Increase / (Decrease) in Invested Capital	18	117	13	-31	74	68	0.00
Enterprise Value (EV)	5,978	8,979	7,008	5,632	63	340	0.00
Market Capitalization	5,919	9,932	7,699	6,199	519	424	424
Book Value per Share	$2.86	$3.79	$2.41	$2.88	$4.49	$16.43	$0.00
Tangible Book Value per Share	$2.85	$3.78	$2.40	$2.86	$4.48	$16.40	$0.00
Total Capital	1,386	1,577	1,025	888	1,196	303	0.00
Total Debt	346	325	281	122	0.00	0.00	0.00
Total Long-Term Debt	346	325	281	122	0.00	0.00	0.00
Net Debt	59	-953	-691	-567	-456	-83	0.00
Capital Expenditures (CapEx)	14	0.00	0.00	42	26	27	21
Debt-free, Cash-free Net Working Capital (DFCFNWC)	720	3.01	-170	32	-39	-63	0.00
Debt-free Net Working Capital (DFNWC)	1,006	1,281	801	721	417	20	0.00
Net Working Capital (NWC)	1,006	1,281	801	721	417	20	0.00
Net Nonoperating Expense (NNE)	-55	189	111	121	102	7.40	1.71
Net Nonoperating Obligations (NNO)	-781	-1,010	-620	-655	-1,053	-235	0.00
Total Depreciation and Amortization (D&A)	23	13	13	14	9.93	5.26	1.68
Debt-free, Cash-free Net Working Capital to Revenue	114.71%	1.05%	-145.55%	46.07%	-51.69%	-105.19%	0.00%
Debt-free Net Working Capital to Revenue	160.43%	449.38%	684.87%	1,047.05%	555.90%	33.80%	0.00%
Net Working Capital to Revenue	160.43%	449.38%	684.87%	1,047.05%	555.90%	33.80%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	367.30M	363.82M	330.13M	0.00	266.01M	0.00	0.00
Adjusted Diluted Earnings per Share	($0.48)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	367.30M	363.82M	330.13M	0.00	266.01M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	367.30M	363.82M	330.13M	0.00	266.01M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-229	-329	-335	-282	-164	-94	-1.07
Normalized NOPAT Margin	-36.47%	-115.55%	-286.37%	-410.03%	-218.79%	-157.03%	-1.70%
Pre Tax Income Margin	-25.21%	-182.41%	-380.94%	-591.63%	-411.05%	-212.27%	-2.56%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

No quarterly metrics and ratios for Legend Biotech are available.

Frequently Asked Questions About Legend Biotech's Financials

When does Legend Biotech's financial year end?

According to the most recent income statement we have on file, Legend Biotech's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Legend Biotech's net income changed over the last 6 years?

Legend Biotech's net income appears to be on an upward trend, with a most recent value of -$177.03 million in 2024, rising from -$2.78 million in 2018. The previous period was -$518.25 million in 2023. Find out what analysts predict for Legend Biotech in the coming months.

What is Legend Biotech's operating income?

Legend Biotech's total operating income in 2024 was -$331.23 million, based on the following breakdown:

Total Gross Profit: $371.01 million
Total Operating Expenses: $702.23 million

How has Legend Biotech revenue changed over the last 6 years?

Over the last 6 years, Legend Biotech's total revenue changed from $63.03 million in 2018 to $627.24 million in 2024, a change of 895.1%.

How much debt does Legend Biotech have?

Legend Biotech's total liabilities were at $629.61 million at the end of 2024, a 5.4% increase from 2023, and a 345.6% increase since 2019.

How much cash does Legend Biotech have?

In the past 5 years, Legend Biotech's cash and equivalents has ranged from $83.36 million in 2019 to $1.28 billion in 2023, and is currently $286.75 million as of their latest financial filing in 2024.

How has Legend Biotech's book value per share changed over the last 6 years?

Over the last 6 years, Legend Biotech's book value per share changed from 0.00 in 2018 to 2.86 in 2024, a change of 286.0%.

Related Companies

This page (NASDAQ:LEGN) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Legend Biotech (LEGN) Financials

Frequently Asked Questions About Legend Biotech's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Legend Biotech (LEGN) Financials

Annual Income Statements for Legend Biotech

Quarterly Income Statements for Legend Biotech

Annual Cash Flow Statements for Legend Biotech

Quarterly Cash Flow Statements for Legend Biotech

Annual Balance Sheets for Legend Biotech

Quarterly Balance Sheets for Legend Biotech

Annual Metrics And Ratios for Legend Biotech

Quarterly Metrics And Ratios for Legend Biotech

Frequently Asked Questions About Legend Biotech's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools